Cargando…
Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients
INTRODUCTION: The increasing prevalence of multiresistant Gram-negative strains in intensive care units (ICUs) has recently rekindled interest in colistin, a bactericidal antibiotic that was used in the 1960s for treatment of infections caused by Gram-negative bacilli. We conducted the present obser...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC270720/ https://www.ncbi.nlm.nih.gov/pubmed/12974973 http://dx.doi.org/10.1186/cc2358 |
_version_ | 1782121047780229120 |
---|---|
author | Markou, Nikolaos Apostolakos, Haralampos Koumoudiou, Christiana Athanasiou, Maria Koutsoukou, Alexandra Alamanos, Ioannis Gregorakos, Leonidas |
author_facet | Markou, Nikolaos Apostolakos, Haralampos Koumoudiou, Christiana Athanasiou, Maria Koutsoukou, Alexandra Alamanos, Ioannis Gregorakos, Leonidas |
author_sort | Markou, Nikolaos |
collection | PubMed |
description | INTRODUCTION: The increasing prevalence of multiresistant Gram-negative strains in intensive care units (ICUs) has recently rekindled interest in colistin, a bactericidal antibiotic that was used in the 1960s for treatment of infections caused by Gram-negative bacilli. We conducted the present observational study to evaluate the efficacy of intravenous colistin in the treatment of critically ill patients with sepsis caused by Gram-negative bacilli resistant to all other antibiotics. PATIENTS AND METHOD: Critically ill patients with sepsis caused by Gram-negative bacilli resistant to all antibiotics with the exception of colistin were treated in the six-bed ICU of a trauma hospital. Diagnosis of infection was based on clinical data and isolation of bacteria, and the bacteria were tested with respect to their susceptibility to colistin. Clinical response to colistin was evaluated. RESULTS: Twenty-four patients (mean age 44.3 years, mean Acute Physiology and Chronic Health Evaluation II score 20.6) received 26 courses of colistin. Clinical response was observed for 73% of the treatments. Survival at 30 days was 57.7%. Deterioration in renal function was observed in 14.3% of 21 patients who were not already receiving renal replacement therapy, but in only one case did this deterioration have serious clinical consequences. CONCLUSION: The lack of a control group in the present study does not allow any definite conclusions to be drawn regarding the clinical effectiveness of colistin. On the other hand, this drug has an acceptable safety profile and its use should be considered in severe infections with multiresistant Gram-negative bacilli. |
format | Text |
id | pubmed-270720 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-2707202003-11-21 Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients Markou, Nikolaos Apostolakos, Haralampos Koumoudiou, Christiana Athanasiou, Maria Koutsoukou, Alexandra Alamanos, Ioannis Gregorakos, Leonidas Crit Care Research INTRODUCTION: The increasing prevalence of multiresistant Gram-negative strains in intensive care units (ICUs) has recently rekindled interest in colistin, a bactericidal antibiotic that was used in the 1960s for treatment of infections caused by Gram-negative bacilli. We conducted the present observational study to evaluate the efficacy of intravenous colistin in the treatment of critically ill patients with sepsis caused by Gram-negative bacilli resistant to all other antibiotics. PATIENTS AND METHOD: Critically ill patients with sepsis caused by Gram-negative bacilli resistant to all antibiotics with the exception of colistin were treated in the six-bed ICU of a trauma hospital. Diagnosis of infection was based on clinical data and isolation of bacteria, and the bacteria were tested with respect to their susceptibility to colistin. Clinical response to colistin was evaluated. RESULTS: Twenty-four patients (mean age 44.3 years, mean Acute Physiology and Chronic Health Evaluation II score 20.6) received 26 courses of colistin. Clinical response was observed for 73% of the treatments. Survival at 30 days was 57.7%. Deterioration in renal function was observed in 14.3% of 21 patients who were not already receiving renal replacement therapy, but in only one case did this deterioration have serious clinical consequences. CONCLUSION: The lack of a control group in the present study does not allow any definite conclusions to be drawn regarding the clinical effectiveness of colistin. On the other hand, this drug has an acceptable safety profile and its use should be considered in severe infections with multiresistant Gram-negative bacilli. BioMed Central 2003 2003-07-28 /pmc/articles/PMC270720/ /pubmed/12974973 http://dx.doi.org/10.1186/cc2358 Text en Copyright © 2003 Markou et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Markou, Nikolaos Apostolakos, Haralampos Koumoudiou, Christiana Athanasiou, Maria Koutsoukou, Alexandra Alamanos, Ioannis Gregorakos, Leonidas Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients |
title | Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients |
title_full | Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients |
title_fullStr | Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients |
title_full_unstemmed | Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients |
title_short | Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients |
title_sort | intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC270720/ https://www.ncbi.nlm.nih.gov/pubmed/12974973 http://dx.doi.org/10.1186/cc2358 |
work_keys_str_mv | AT markounikolaos intravenouscolistininthetreatmentofsepsisfrommultiresistantgramnegativebacilliincriticallyillpatients AT apostolakosharalampos intravenouscolistininthetreatmentofsepsisfrommultiresistantgramnegativebacilliincriticallyillpatients AT koumoudiouchristiana intravenouscolistininthetreatmentofsepsisfrommultiresistantgramnegativebacilliincriticallyillpatients AT athanasioumaria intravenouscolistininthetreatmentofsepsisfrommultiresistantgramnegativebacilliincriticallyillpatients AT koutsoukoualexandra intravenouscolistininthetreatmentofsepsisfrommultiresistantgramnegativebacilliincriticallyillpatients AT alamanosioannis intravenouscolistininthetreatmentofsepsisfrommultiresistantgramnegativebacilliincriticallyillpatients AT gregorakosleonidas intravenouscolistininthetreatmentofsepsisfrommultiresistantgramnegativebacilliincriticallyillpatients |